S&P 500   4,388.86 (-0.48%)
DOW   34,397.63 (+0.10%)
QQQ   348.32 (-1.41%)
AAPL   161.20 (-0.26%)
MSFT   293.83 (-0.86%)
FB   305.33 (-1.09%)
GOOGL   2,576.17 (-1.53%)
AMZN   2,828.00 (-2.18%)
TSLA   941.48 (+1.23%)
NVDA   227.98 (-2.46%)
BABA   119.71 (-0.55%)
NIO   24.25 (-2.49%)
AMD   113.26 (-2.81%)
CGC   7.43 (+0.41%)
MU   82.04 (-1.10%)
GE   91.32 (-5.77%)
T   26.46 (+0.46%)
F   20.16 (-1.13%)
DIS   136.90 (-0.41%)
AMC   16.38 (-1.56%)
PFE   52.74 (+2.33%)
ACB   4.25 (-1.62%)
BA   204.16 (-0.02%)
S&P 500   4,388.86 (-0.48%)
DOW   34,397.63 (+0.10%)
QQQ   348.32 (-1.41%)
AAPL   161.20 (-0.26%)
MSFT   293.83 (-0.86%)
FB   305.33 (-1.09%)
GOOGL   2,576.17 (-1.53%)
AMZN   2,828.00 (-2.18%)
TSLA   941.48 (+1.23%)
NVDA   227.98 (-2.46%)
BABA   119.71 (-0.55%)
NIO   24.25 (-2.49%)
AMD   113.26 (-2.81%)
CGC   7.43 (+0.41%)
MU   82.04 (-1.10%)
GE   91.32 (-5.77%)
T   26.46 (+0.46%)
F   20.16 (-1.13%)
DIS   136.90 (-0.41%)
AMC   16.38 (-1.56%)
PFE   52.74 (+2.33%)
ACB   4.25 (-1.62%)
BA   204.16 (-0.02%)
S&P 500   4,388.86 (-0.48%)
DOW   34,397.63 (+0.10%)
QQQ   348.32 (-1.41%)
AAPL   161.20 (-0.26%)
MSFT   293.83 (-0.86%)
FB   305.33 (-1.09%)
GOOGL   2,576.17 (-1.53%)
AMZN   2,828.00 (-2.18%)
TSLA   941.48 (+1.23%)
NVDA   227.98 (-2.46%)
BABA   119.71 (-0.55%)
NIO   24.25 (-2.49%)
AMD   113.26 (-2.81%)
CGC   7.43 (+0.41%)
MU   82.04 (-1.10%)
GE   91.32 (-5.77%)
T   26.46 (+0.46%)
F   20.16 (-1.13%)
DIS   136.90 (-0.41%)
AMC   16.38 (-1.56%)
PFE   52.74 (+2.33%)
ACB   4.25 (-1.62%)
BA   204.16 (-0.02%)
S&P 500   4,388.86 (-0.48%)
DOW   34,397.63 (+0.10%)
QQQ   348.32 (-1.41%)
AAPL   161.20 (-0.26%)
MSFT   293.83 (-0.86%)
FB   305.33 (-1.09%)
GOOGL   2,576.17 (-1.53%)
AMZN   2,828.00 (-2.18%)
TSLA   941.48 (+1.23%)
NVDA   227.98 (-2.46%)
BABA   119.71 (-0.55%)
NIO   24.25 (-2.49%)
AMD   113.26 (-2.81%)
CGC   7.43 (+0.41%)
MU   82.04 (-1.10%)
GE   91.32 (-5.77%)
T   26.46 (+0.46%)
F   20.16 (-1.13%)
DIS   136.90 (-0.41%)
AMC   16.38 (-1.56%)
PFE   52.74 (+2.33%)
ACB   4.25 (-1.62%)
BA   204.16 (-0.02%)
NASDAQ:IKNA

Ikena Oncology Stock Forecast, Price & News

$10.65
-0.11 (-1.02%)
(As of 01/25/2022 02:20 PM ET)
Add
Compare
Today's Range
$10.42
▼
$10.84
50-Day Range
$10.75
▼
$16.70
52-Week Range
$9.63
▼
$37.61
Volume
3,532 shs
Average Volume
121,253 shs
Market Capitalization
$382.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive IKNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter.


About Ikena Oncology

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Headlines

Short Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Rises By 29.5%
January 18, 2022 |  americanbankingnews.com
Ikena Oncology, Inc. (NASDAQ:IKNA) Given Consensus Recommendation of "Buy" by Analysts
January 17, 2022 |  americanbankingnews.com
We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate
December 25, 2021 |  nasdaq.com
Here's Why We're Not Too Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Situation
December 23, 2021 |  finance.yahoo.com
IKNA
December 14, 2021 |  seekingalpha.com
Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer
December 8, 2021 |  finance.yahoo.com
Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175
November 12, 2021 |  finance.yahoo.com
Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update
November 10, 2021 |  finance.yahoo.com
Ikena Oncology to Participate in November 2021 Virtual Investor Conferences
November 4, 2021 |  finance.yahoo.com
Ikena Oncology Reports FDA Acceptance Of Investigational New Drug Application For Novel TEAD Inhibitor Candidate, IK-930
November 4, 2021 |  benzinga.com
Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930
November 2, 2021 |  finance.yahoo.com
Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
October 7, 2021 |  finance.yahoo.com
Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
October 1, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IKNA
Previous Symbol
CUSIP
N/A
CIK
1835579
Web
ikenaoncology.com
Phone
857-273-8343
Fax
N/A
Employees
33
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.24
Quick Ratio
8.24

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
35,907,000
Free Float
N/A
Market Cap
$382.41 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/25/2022
Next Earnings (Estimated)
2/09/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.85 out of 5 stars

Medical Sector

780th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

124th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Ikena Oncology (NASDAQ:IKNA) Frequently Asked Questions

Is Ikena Oncology a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ikena Oncology in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ikena Oncology stock.
View analyst ratings for Ikena Oncology or view top-rated stocks.

Are investors shorting Ikena Oncology?

Ikena Oncology saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,890,000 shares, an increase of 29.5% from the December 15th total of 1,460,000 shares. Based on an average trading volume of 153,700 shares, the short-interest ratio is presently 12.3 days.
View Ikena Oncology's Short Interest.

When is Ikena Oncology's next earnings date?

Ikena Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Ikena Oncology.

How were Ikena Oncology's earnings last quarter?

Ikena Oncology, Inc. (NASDAQ:IKNA) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.02. The business earned $3.75 million during the quarter, compared to analyst estimates of $2.92 million.
View Ikena Oncology's earnings history.

What price target have analysts set for IKNA?

5 analysts have issued 12-month target prices for Ikena Oncology's shares. Their forecasts range from $25.00 to $27.00. On average, they expect Ikena Oncology's stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 144.1% from the stock's current price.
View analysts' price targets for Ikena Oncology or view top-rated stocks among Wall Street analysts.

Who are Ikena Oncology's key executives?

Ikena Oncology's management team includes the following people:
  • Dr. Mark Manfredi, Pres. CEO & Director (Age 50)
  • Mr. Douglas R. Carlson, COO & Exec. VP of Fin. (Age 42)
  • Mr. Jeffrey Ecsedy Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Sergio L. Santillana M.B.A., M.Sc., MSc, M.D., Chief Medical Officer (Age 58)
  • Ms. Maude Tessier Ph.D., Chief Bus. Officer (Age 43)
  • Mr. Alfredo Castro Ph.D., Sr. VP of Discovery
  • Mr. Alexander Constan Ph.D., Sr. VP of Non Clinical Safety & DMPK
  • Dr. Michelle Zhang Ph.D., Sr. vice Pres of Translational Research & Early Devel.

When did Ikena Oncology IPO?

(IKNA) raised $125 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO.

What is Ikena Oncology's stock symbol?

Ikena Oncology trades on the NASDAQ under the ticker symbol "IKNA."

Who are Ikena Oncology's major shareholders?

Ikena Oncology's stock is owned by a number of retail and institutional investors. Top institutional investors include Baystate Wealth Management LLC (0.01%). Company insiders that own Ikena Oncology stock include Jean Francois Formela, Venture Fund Xi LP Atlas and Xiaoyan Michelle Zhang.
View institutional ownership trends for Ikena Oncology.

Which major investors are buying Ikena Oncology stock?

IKNA stock was bought by a variety of institutional investors in the last quarter, including Baystate Wealth Management LLC.
View insider buying and selling activity for Ikena Oncology or or view top insider-buying stocks.

How do I buy shares of Ikena Oncology?

Shares of IKNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ikena Oncology's stock price today?

One share of IKNA stock can currently be purchased for approximately $10.65.

How much money does Ikena Oncology make?

Ikena Oncology has a market capitalization of $382.41 million.

How many employees does Ikena Oncology have?

Ikena Oncology employs 33 workers across the globe.

What is Ikena Oncology's official website?

The official website for Ikena Oncology is ikenaoncology.com.

Where are Ikena Oncology's headquarters?

Ikena Oncology is headquartered at 645 SUMMER STREET SUITE 101, BOSTON MA, 02210.

How can I contact Ikena Oncology?

Ikena Oncology's mailing address is 645 SUMMER STREET SUITE 101, BOSTON MA, 02210. The company can be reached via phone at 857-273-8343 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.